Equity Profile
Pre-Earnings Brief
Kiniksa Pharmaceuticals International, plc (KNSA) is a biotechnology company focused on developing innovative therapies for patients with unmet medical needs. Operating in the health care sector, Kiniksa is particularly relevant in the context of increasing demand for effective treatments in chronic and rare diseases.
Earnings Per Share (EPS)
EPS is a key indicator of the company's profitability and will help gauge financial health this quarter.
Revenue
Revenue figures will provide insight into the company's sales performance and market demand for its products.
Wall Street expectations, options signals, track record, and call prep available with Pro.
EPS Beat Streak
1Q
EPS Beat Rate
50%
Avg EPS Surprise
-110.97%
Avg Stock Reaction
+6.62%
In Q1-2026, Kiniksa reported an EPS of $0.27, significantly beating expectations of $0.18. The stock reacted positively, gaining 23.48% the following day.
Management Promises & Guidance
Overall expectations for Kiniksa's upcoming earnings are mixed, with no analyst estimates available. The company's recent performance has shown volatility, with both beats and misses in previous quarters.
Bull Case
If Kiniksa continues to show strong EPS growth and effective product sales, it could attract more investor interest and push the stock higher.
Bear Case
On the other hand, if the company fails to meet expectations or shows declining sales, it could lead to a significant drop in stock price.
Earnings Per Share (EPS)
N/AEPS is a key indicator of the company's profitability and will help gauge financial health this quarter.
Revenue
N/ARevenue figures will provide insight into the company's sales performance and market demand for its products.
Expectations
The print will turn on these two things.
Q1
What will the EPS be for Q2-2026?
The EPS figure will be crucial in determining if the company can maintain its recent growth trajectory and investor confidence.
Q2
How is Kiniksa's revenue trending compared to last quarter?
Revenue trends will indicate the effectiveness of Kiniksa's products in the market and overall demand.
Edge
Why consensus could be wrong
The Street may be underestimating Kiniksa's ability to sustain its EPS growth, given recent positive trends in product performance and market demand.
Supporting Evidence
Kiniksa's recent EPS surprise of +50% indicates strong operational performance.
The options market is pricing a significant move, suggesting heightened expectations that may not be reflected in analyst estimates.
Key Risk
If the EPS comes in above $0.30, it could challenge the current cautious sentiment and lead to a reevaluation of growth potential.
Edge
Pre-commit to what would confirm each case.
The market is debating whether Kiniksa can sustain its recent positive momentum or if it will face challenges in maintaining profitability.
Bull Confirmed If
An EPS of $0.30 or higher would confirm the bullish sentiment and suggest continued growth.
Bear Confirmed If
An EPS below $0.18 would signal potential issues and confirm bearish concerns.
Pre-Earnings Positioning
Implied Move
±25.21%
Historical Avg
±13.3%
The options market is pricing in a significant potential move, indicating that traders expect volatility around the earnings report.
Options are pricing ±25.2% while KNSA has averaged ±13.3% over the last 8 prints — setup is pricing rich.
ATM IV
0.5%
30d HV
69.7%
Edge
Cross-company pattern from 30 similar setups.
Prior-quarter beat + options rich in Health Care
n=30Fade rate: X of Y (Z%)
This setup has occurred 30 times across Health Care in the last 2 years. The average absolute 1-day move is 4.6%, with a raw directional average of +0.8% (modestly positive historical bias).
Edge
Open-market trades by officers, directors, and 10%+ holders over the trailing 90 days.
Bought
$0.00
0 sh
0 insiders
Sold
$388,834.32
8,328 sh
2 insiders
Net
$388,834.32
Net selling
Most Active Insiders· 2 open-market trades
$309,321.25
Net selling
$79,513.07
Net selling
Recent Transactions
Apr 9, 2026 · @ $46.69
6,625 sh
$309,321.25
Apr 9, 2026 · @ $46.69
1,703 sh
$79,513.07
Open-market trades only (Form 4 codes P/S). Awards, exercises, and tax-withholding excluded as routine compensation noise.
Preparation
Likely market behavior by outcome — not investment advice.
Beat & Raise
If Kiniksa beats expectations, history suggests the stock could rise by an average of 19.81%, confirming strong operational performance.
In-Line / Cautious
If results are in line with expectations, the stock may see a muted reaction, reflecting uncertainty in future growth.
Miss
If Kiniksa misses expectations, the stock could drop by an average of 6.58%, indicating investor disappointment.
Preparation
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
Southern Copper Corporation